Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends BioPharma DiveWave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.Clinical DataMetabolic & GLP-1Read full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Maze tumbles despite positive data for kidney disease drugNext: FDA clears Denali drug in ‘clear step’ for rare disease biotechs Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
